Human effectors of acute and chronic GVHD overexpress CD83 and predict mortality.
Shernan G HoltanConstanza Savid-FronteraKelly WaltonAnne A EatonConnor DemorestAndrea HoeschenLing ZhangKayla M ReidTony KurianZena SayeghEstefania JuliaJoseph E MaakaronVeronika BachanovaNajla El JurdiMargaret L MacMillanDaniel J WeisdorfMartin FelicesJeffrey S MillerBruce R BlazarMarco L DavilaBrian C BettsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
CD83 is a promising diagnostic marker of GVHD and warrants further investigation as a therapeutic target of both GVHD and AML relapse after alloHCT.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- acute myeloid leukemia
- endothelial cells
- acute lymphoblastic leukemia
- liver failure
- drug induced
- nk cells
- cardiovascular events
- respiratory failure
- induced pluripotent stem cells
- risk factors
- pluripotent stem cells
- aortic dissection
- intensive care unit
- hepatitis b virus